Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys, a Germany-based biotechnology company, has appointed Arndt Schottelius as its first chief development officer, responsible for coordinating the group's expanding therapeutic antibody development activities including pre-clinical and clinical drug development. The appointment of Dr Schottelius will take effect on December 29, 2008.
Subscribe to our email newsletter
Dr Schottelius joins MorphoSys from Genentech, South San Francisco, where he served as the director of immunology, tissue growth and repair early development and most recently as medical director, immunology development, directing late-stage clinical development studies for the anti-CD20 antibodies Rituximab and Ocrelizumab in rheumatoid arthritis.
Prior to his position at Genentech, Dr Schottelius held science and management positions in immunology research at Berlex Biosciences, California, US, and Schering AG, Berlin, Germany.
Gerald Moller, chairman of MorphoSys, said: “I am delighted to welcome Dr Schottelius to the management team of MorphoSys. He brings unique knowledge and a track record in drug development as well as profound management expertise from Genentech that will assist MorphoSys in achieving its pipeline growth plans over the coming years.”